What changed: Imatinib-resistant GIST

Cancer page →

Every dated change on the records linked to Imatinib-resistant GIST, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Trial result1Milestone5This record1

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-17This recordImatinib-resistant GIST
Facts on this page last checked
When this page itself was last checked or edited.

2022 · 1

2022MilestoneA Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib
INTRIGUE: ripretinib not superior to sunitinib second line; genotype subgroups diverge
A milestone in how this cancer is treated.

2020 · 2

2013 · 1

2013MilestoneRegorafenib
GRID: regorafenib approved in the third line
A milestone in how this cancer is treated.

2006 · 1

2006MilestoneSunitinib
Sunitinib approved after imatinib failure
A milestone in how this cancer is treated.

2005 · 1

2005MilestoneKIT
Secondary KIT mutations identified as the mechanism of imatinib resistance (Antonescu, Heinrich)
A milestone in how this cancer is treated.